SNORD116-19: A Potential Drug Target and Biomarker (G727708)

Target Name: SNORD116-19

NCBI ID: G727708

SNORD116-19

Other Name(s): Small nucleolar RNA, C/D box 116-19 | HBII-85-19 | small nucleolar RNA, C/D box 116-19

SNORD116-19: A Potential Drug Target and Biomarker

Small nucleolar RNA (snRNA) is a non-coding RNA molecule that plays a crucial role in various cellular processes, including DNA replication, gene expression, and RNA processing. One of the well-known snRNAs is SNORD116-19, which is located within the C/D box region on chromosome 17.

The C/D box region is a common structural feature in snRNAs, which is composed of a conserved core and a variable region. The conserved core is responsible for maintaining the stability of the RNA molecule, while the variable region is involved in specific functions, such as localization and interaction with other molecules. The SNORD116-19 variable region contains several highly conserved and unique sequences that are associated with its function in regulating gene expression.

Several studies have identified SNORD116-19 as a potential drug target and biomarker. Its unique structure and function make it an attractive target for small molecule inhibitors, which can be used to treat various diseases, including neurodegenerative disorders, cancer, and autoimmune diseases.

Targeting SNORD116-19

The SNORD116-19 protein is a key regulator of gene expression and has been shown to play a role in various cellular processes. It is a nuclear protein that is expressed in a variety of tissues and cells, including brain, muscle, and organs. SNORD116-19 is involved in the regulation of DNA replication, cell growth, and apoptosis, which are critical processes for the maintenance of cellular homeostasis.

One of the unique features of SNORD116-19 is its ability to interact with other proteins. It has been shown to interact with several key transcription factors, including nuclear factor E2F1, which plays a critical role in the regulation of gene expression. SNORD116-19 has also been shown to interact with the protein heat shock protein (Hsp70), which is involved in the regulation of stress responses and DNA damage repair.

In addition to its interactions with other proteins, SNORD116-19 has also been shown to play a role in the regulation of protein translation. It has been shown to interact with the protein translation factor (eIF4F), which is involved in the regulation of protein translation from mRNA to protein. This interaction between SNORD116-19 and eIF4F suggests that it may be involved in the regulation of protein synthesis, which is critical for the development and progression of various diseases.

As a potential drug target, SNORD116-19 is an attractive target for small molecule inhibitors. Its unique structure and function make it an attractive target for inhibitors that can modulate its activity, such as small molecule inhibitors of the RNA polymerase II (RNA-P2) complex, which is involved in the regulation of gene expression.

Biomarker potential

SNORD116-19 has also been shown to be involved in the regulation of cancer cell growth and progression. Its expression is often increased in various types of cancer, including breast cancer, lung cancer, and colorectal cancer. This suggests that SNORD116-19 may be a useful biomarker for the diagnosis and treatment of these diseases.

In addition to its potential as a drug target, SNORD116-19 may also be used as a biomarker for certain neurological disorders. Its expression is often increased in various types of neurodegenerative disorders, including Alzheimer's disease, Parkinson's disease, and Huntington's disease. This suggests that SNORD116-19 may be a useful biomarker for the diagnosis and treatment of these disorders.

Conclusion

SNORD116-19 is a unique and

Protein Name: Small Nucleolar RNA, C/D Box 116-19

The "SNORD116-19 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SNORD116-19 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets